Perspectives

Drug Pipeline Quarterly Update: September 2021

Drugs in review, drugs with expiring patents, generic availability and more.

September 30, 2021

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.

September 2021 Quarterly Drug Pipeline Update
September 2021 Quarterly Specialty Drug Pipeline Update

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit www.primetherapeutics.com and www.magellanrx.com, or follow us on Twitter at @Prime_PBM and @Magellan_Rx.

Related news

Perspectives

January 24, 2023

Traditional Drug Pipeline Update: January 2023

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Read More

Perspectives

January 24, 2023

Specialty Pipeline Monthly Update: January 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Read More

Perspectives

January 13, 2023

February 2023 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Read More
View all news